Dr. Patricia Lee

Pathology
Mays MD PA
451 N Texas Ave, 
Webster, TX 
Mays MD PA
451 N Texas Ave, 
Webster, TX 

Overview

Patricia Lee is a Pathologist practicing medicine in Webster, Texas.

Her clinical expertise encompasses Plaque Psoriasis, Psoriasis, Atopic Dermatitis, and Genital Herpes.

She is actively involved in clinical research, co-authoring 4 peer reviewed articles and participating in 9 clinical trials.

Specialties

Pathology

Licenses

Dermatology in TX

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID

Locations

Mays MD PA
451 N Texas Ave, Webster, TX 77598

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: April 16, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 2/Phase 3
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multi-Center, Randomized, Double-Blind, Placebo-controlled Proof-of-Activity Study With Orticumab in Subjects With Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors
A Multi-Center, Randomized, Double-Blind, Placebo-controlled Proof-of-Activity Study With Orticumab in Subjects With Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors
Enrollment Status: Completed
Publish Date: February 02, 2024
Intervention Type: Drug
Study Drug: Orticumab
Study Phase: Phase 2
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
A Phase 2a Study to Evaluate Safety, Tolerability, and Efficacy of PRCL-02 in Patients With Moderate to Severe Chronic Plaque Psoriasis
A Phase 2a Study to Evaluate Safety, Tolerability, and Efficacy of PRCL-02 in Patients With Moderate to Severe Chronic Plaque Psoriasis
Enrollment Status: Completed
Publish Date: March 30, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

4 Total Publications

Spesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: Results from a multicentre, randomized, double-blind, placebo-controlled, phase IIa study.
Spesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: Results from a multicentre, randomized, double-blind, placebo-controlled, phase IIa study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: March 28, 2022
Similar Doctors
Expertise in
5
conditions
Dr. Ronald Rapini
Dermatology | Pathology
Expertise in
5
conditions
Dr. Ronald Rapini
Dermatology | Pathology
6500 West Loop S # 200a, 
Bellaire, TX 
 (23.2 miles away)
713-704-4000
Languages Spoken:
English
See accepted insurances

Ronald Rapini is a Dermatologist and a Pathologist practicing medicine in Bellaire, Texas. Dr. Rapini is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Actinic Keratosis, Hartsfield Syndrome, Basal Cell Skin Cancer, and Warts.

Expertise in
2
conditions
Dr. Natasha Klimas
Dermatology | Pathology | Laboratory Medicine
Expertise in
2
conditions
Dr. Natasha Klimas
Dermatology | Pathology | Laboratory Medicine
6411 Fannin St, 
Houston, TX 
 (20.4 miles away)
713-500-5301
Languages Spoken:
English
See accepted insurances

Natasha Klimas is a Dermatologist and a Pathologist practicing medicine in Houston, Texas. Dr. Klimas is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Hidradenitis Suppurativa, Bullae, Comedones, and Epidermoid Cyst.

Expertise in
0
conditions
Dr. Miguel A. Pappolla
Neurology | Psychiatry | Pathology
Expertise in
0
conditions
Dr. Miguel A. Pappolla
Neurology | Psychiatry | Pathology

St. Michael's Nuerology And Pain Medicine

2646 S Loop West Ste 106, 
Houston, TX 
 (19.5 miles away)
713-661-0300
Experience:
32+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Pappolla is Board Certified in Neurology, Pain Medicine (Anesthesia Fellowship). He served as a consultant for the National Institutes of Health in the United States including being a chartered member of numerous study sections for over 25 years. He served as a full professor or faculty at several top medical schools (LSU New Orleans, Mount Sinai Medical School in New York City, University of Texas) where he taught Neurosciences to medical students and medical residents for over 20 years. Currently, he holds a hybrid academic-private practice position in the Houston area. Dr. Pappolla's training included 3 complete medical residencies and 2 fellowships (Neurology, Clinical Pathology, Anatomic Pathology, Neuropathology, Pain Medicine), a PhD in human aging with a postdoc/sabbatical in molecular biology followed by over almost 30 years of academic and private practice experience. He holds active board certifications in these 5 areas (Neurology, Clinical Pathology, Anatomic Pathology, Neurology, Pain Medicine). Some of his research work is cited in several thousand textbooks worldwide, with many papers reaching from 300 to over 1000 citations in peer-reviewed journals. His clinical expertise encompasses Fibromyalgia, Chronic Pain, and Traumatic Brain Injury. Dr. Pappolla is board certified in Neurology, Neuropathology, Clinical Pathology, Anatomic Pathology, and Pain Medicine. Dr. Pappolla is currently accepting new patients.

Frequently Asked Questions about Dr. Patricia Lee

How do I make an appointment with Dr. Patricia Lee?

You can book an appointment with Dr. Patricia Lee by calling their office at 281-333-2288. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Patricia Lee a top-rated expert for Plaque Psoriasis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Patricia Lee is classified as an Experienced expert for Plaque Psoriasis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Patricia Lee specialize in?

While Dr. Patricia Lee is a Pathology, they have specific expertise in Plaque Psoriasis, Psoriasis, and Atopic Dermatitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pathology.

Does Dr. Patricia Lee participate in research or clinical trials?

Yes. Dr. Patricia Lee has published 4 articles and abstracts on conditions like Plaque Psoriasis. You can view a list of Dr. Patricia Lee's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Patricia Lee accept my insurance?

Dr. Patricia Lee accepts most major insurance plans, including Cigna and Devoted Health. We recommend calling the office directly at 281-333-2288 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lee's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile